SCHEDULE: Vanguard Discloses 7.37% Stake in Regeneron Pharmaceuticals

Vanguard Capital Management has reported a beneficial ownership of 7.37% in Regeneron Pharmaceuticals Inc., holding over 7.6 million shares as of March 31, 2026.

Summary

• Vanguard Capital Management, through its affiliates and managed accounts, now beneficially owns 7,660,810 shares of Regeneron Pharmaceuticals Inc. common stock.
• This holding represents 7.37% of the class of securities.
• Vanguard has sole voting power over 1,005,897 shares and sole dispositive power over all 7,660,810 shares.
• The filing is made under Schedule 13G, indicating Vanguard is an investment adviser and the shares were acquired in the ordinary course of business, not for the purpose of influencing control.
• The reporting date for this ownership stake is March 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a standard disclosure of institutional ownership, indicating Vanguard's continued investment in Regeneron without providing new operational or financial performance data.

Positives

• Vanguard's significant stake indicates confidence in Regeneron's long-term prospects.
• The filing confirms Vanguard's role as a major institutional investor, which can provide stability and liquidity to the stock.

Risks

• While not explicitly stated as a risk in this filing, significant institutional ownership can sometimes lead to increased volatility if large blocks of shares are traded.
• The filing does not provide forward-looking statements or specific business updates, so potential business risks for Regeneron are not detailed here.

Future Outlook

This filing is a disclosure of current ownership and does not contain forward-looking statements or guidance regarding Regeneron Pharmaceuticals Inc.'s future performance.

Industry Context

StockSavvy.ai notes that Vanguard's increased stake in Regeneron Pharmaceuticals Inc. aligns with broader trends of large asset managers consolidating positions in leading biotechnology firms, particularly those with strong drug pipelines and established market presence.

Stakeholder Impact

• Shareholders: The filing confirms a major institutional investor's significant holding, which can be viewed positively for stock stability and potential future institutional interest.
• Vanguard Clients: Clients invested in Vanguard funds that hold Regeneron stock benefit from the company's performance.
• Regeneron Management: The company is aware of Vanguard's substantial investment and voting power.

Next Steps

• Vanguard will continue to monitor its investment in Regeneron Pharmaceuticals Inc.
• Regeneron Pharmaceuticals Inc. will continue its operations and business activities.

Key Dates

Keywords

Regeneron Pharmaceuticals, Vanguard Capital Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Adviser